AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00132821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
Study NCT00132821 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Nicotine Patch
Description: 21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
Study NCT00132821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Bupropion
Description: Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
Study NCT00132821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo transdermal nicotine patch
Description: 21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
Study NCT00490763 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: 7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
Study NCT00923819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass
Description: Patients are referred to Morbid Obesity Center from Vestfold Hospital Trust and other hospitals in Norway. The procedure will take place at Morbid Obesity Center, Vestfold Hospital Trust.
Study NCT00923819 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard conservative treatment
Description: Participants from Child Obesity Registry who undergoes conservative treatment at Morbid Obesity Center, Vestfold Hospital Trust.
Study NCT00751114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
Study NCT00751114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Oral administration. 100 mg film-coated tablets.
Study NCT00751114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients continued with metformin as usual oral anti-diabetic treatment.
Study NCT00751114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients continued with metformin as usual oral anti-diabetic treatment.
Study NCT01790971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Morphine
Description: Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
Study NCT01790971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No Intrathecal Morphine
Description: Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
Study NCT03143868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Modality
Description: The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
Study NCT03143868 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Modality
Description: The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
Study NCT03498781 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-only
Description: Participants will write goals related to exercise, the most desired outcome of reaching their goals, anticipated obstacles/barriers which may prevent them from achieving their goals, and if-then statements proactively describing how to overcome or avoid obstacles.
Study NCT00622531 — intervention group
Intervention type: DEVICE
Intervention: BNP assay (Siemens ADVIA Centaur BNP)
Description: Diagnostic test
Study NCT00622531 — intervention group
Intervention type: OTHER
Intervention: hidden BNP value
Description: no intervention
Study NCT03299049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Tablets
Description: CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
Study NCT03498781 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Participants will be asked to identify stress-reduction techniques which they can use in their daily lives and will be encouraged to practice them as necessary.
Study NCT02626572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 5mg
Description: S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
Study NCT02626572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 15mg
Description: S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
Study NCT02626572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S47445 50mg
Description: S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
Study NCT02626572 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
Study NCT03299049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Tablets
Description: RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light.
Study NCT03690037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: Tranexamic Acid: 100 MG/ML Solution for injection
Study NCT03299049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injectable Suspension
Description: CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.
Study NCT03690037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 500 MG
Description: Tranexamic Acid: Tranexamic Acid 500mg Tablets
Study NCT02541916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controlled weaning of immunosuppression
Description: At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy \& LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
Study NCT03299049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilpivirine Injectable Suspension
Description: RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
Study NCT04563156 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Function Test
Description: Lung Function Test at 1, 4, 6 and 12 months after discharge. Computerized tomography scan at 6 months after discharge. Cardiopulmonary Exercise Testing at 6 months after discharge
Study NCT02731339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Mouse® measurement
Description: The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
Study NCT02731339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low back pain intensity measurement
Description: Low back pain intensity of the patients was questioned by Visual Analogue Scale
Study NCT02731339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urogenital symptoms measurement
Description: The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
Study NCT02731339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disability caused by low back pain
Description: Disability caused by low back pain was assessed with the Oswestry Disability Index
Study NCT01261234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol or Non-Cilostazol
Description: Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
Study NCT01193192 — intervention group
Intervention type: OTHER
Intervention: Neevo®
Description: A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid
Study NCT01261234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol or Non-Cilostazol
Description: Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
Study NCT01209611 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
Study NCT03290248 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244 suspension
Description: B244 suspension in 30ml/bottle
Study NCT01193192 — intervention group
Intervention type: OTHER
Intervention: Prenatal vitamins
Description: for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
Study NCT00754728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JACTAX DES
Description: Drug Eluting Stent
Study NCT00786136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: rosuvastatin
Study NCT00786136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rosuvastatin
Description: rosuvastatin
Study NCT03714906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Stellate ganglion block will consist of an injection of 0.25% bupivacaine placed under ultrasound guidance by a trained anesthesiologist in the pre-operative holding area prior to surgery.
Study NCT01469806 — intervention group
Intervention type: DEVICE
Intervention: Zimmer Gender Solutions PFJ Knee Prosthesis
Description: Partial knee arthroplasty of the patello-femoral joint
Study NCT03206242 — intervention group
Intervention type: OTHER
Intervention: Physiotherapy
Description: Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
Study NCT01518426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG Recording (Emotiv)
Description: Record EEG during auditory oddball paradigms:~* with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)~* with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)
Study NCT00789958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Adjuvant chemotherapy: 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle~Chemoradiotherapy: 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT
Study NCT00789958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m\^2, IV, Days 1 \& 8 of each cycle
Study NCT00789958 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Description: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
Study NCT00789958 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
Study NCT00980980 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine bath and nasal mupirocin
Description: The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
Study NCT04073940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Ballet Program
Description: All classes will be offered in a set schedule convenient for all participants. Classes will be taught by the PI, who has extensive dance training expertise. The targeted ballet program consists of an initial period of dance movements while sitting in chairs (20min), followed by exercises holding onto the ballet barres mounted to the walls in the Neuroscience of Dance on Health and Disability Laboratory (20min), followed by locomotive dance movements (20min). The dance moves are based on the Ballet I Syllabus of the Royal Academy of Dancing and the Cecchetti Council of America, designed for eight-year-old students with no necessary previous training in ballet.
Study NCT03290248 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle, 30ml/bottle
Study NCT00561886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: One inhalation of 24µg Formoterol
Study NCT02482519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High calorie diet
Description: High calorie diet for 10 days
Study NCT02482519 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fasting
Description: 10 day fast
Study NCT02306577 — intervention group
Intervention type: DRUG
Intervention: STRIBILD
Description: Taking oral 1 STRIBILD tablet once a day for 48 weeks
Study NCT00004124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Study NCT00004124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Study NCT00004124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin
Study NCT00004124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Study NCT00004124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitoxantrone hydrochloride
Study NCT00004124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT03887624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Description: 2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
Study NCT03887624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 times/day, take it orally after breakfast/dinner; take 500mg in the morning and 500mg in the evening on day1, 500mg in the morning and 750mg in the evening on day2, 750mg in the morning and 750mg in the evening on day3, 750mg in the morning and 1000mg in the evening on day4, 1000mg in the morning and 1000mg in the evening on day5, maintain this dose until the end of treatment for 2 weeks.
Study NCT03887624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: 1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
Study NCT03096002 — intervention group
Intervention type: BEHAVIORAL
Intervention: Lifestyle change
Description: The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
Study NCT04353921 — intervention group
Intervention type: OTHER
Intervention: No intervention will be administered as part of this study.
Description: No intervention will be administered as part of this study.
Study NCT02508688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: thoracoscopic diaphragmatic repair
Description: patients with refractory hepatic hydrothorax (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
Study NCT03887624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 1 time/day, 20mg/day, take it orally after breakfast, take it for 4 weeks without interruption.
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR440340
Description: Pharmaceutical form: Solution for injection; Route of administration: SC
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Solution for injection; Route of administration: SC
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler Route of administration: Inhaled
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Study NCT03546907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care
Description: Pharmaceutical form: Aerosol or Dry Powder inhaler; Route of administration: Inhaled
Study NCT03127410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar traction
Description: Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
Study NCT02223455 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Hygiene Signs
Description: Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
Study NCT02223455 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hand Hygiene Signs
Description: Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
Study NCT00516633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extra information and support
Description: Four group discussions with parents in close connection to diagnosing the children
Study NCT02375958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA062
Study NCT03081533 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circle Dance Program (CircleCare)
Description: Circle Dances derives from folk dances, but their current repertoire encompasses traditional and contemporary dances from diverse nations and cultures around the world. Most of the choreographies are danced with the participants placed in a circle, holding hands, repeating a pattern of steps to the rhythm of the music.
Study NCT01007539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CDP-choline
Description: The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
Study NCT01007539 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (fructose)
Description: The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.